In a highly disappointing yet not all-too-surprising news release earlier today, Eli Lilly & Company (NYSE: LLY) says that its late-stage drug solanezumab failed to improve cognition in patients diagnosed with mild to moderate Alzheimer’s disease. The failure marks the latest in a series of disappointing flops in the indication, and it serves as an important reminder that Alzheimer’s drug development is anything but easy.
